Translator Disclaimer
13 July 2009 Targeted two-photon PDT photo-sensitizers for the treatment of subcutaneous tumors
Author Affiliations +
Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73803Z (2009)
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States
New porphyrin-based photo-sensitizers have been designed, synthesized and characterized that exhibit greatly enhanced intrinsic two-photon absorption. These new photo-sensitizers have been incorporated into triad formulations that also incorporate Near-infrared (NIR) imaging agents, and small-molecule targeting agents that direct the triads to cancerous tumors' over-expressed receptor sites. PDT can be initiated deep into the tissue transparency window at 780-800 nm utilizing a regeneratively amplified Ti:sapphire laser using 100-150 fs pulses of 600-800 mW. Human tumor xenografts of human breast cancer (MDA-MB-231) and both small SCLC (NCI-H69) and NSCLC (A-459) have been successfully treated using octreotate targeting of over-expressed SST2 receptors. In particular, the lung cancer xenografts can be successfully treated by irradiating from the side of the mouse opposite the implanted tumor, thereby passing through ca. 2 cm of mouse skin, tissue and organs with no discernible damage to healthy tissue while causing regression in the tumors. These results suggest a new PDT paradigm for the noninvasive treatment of subcutaneous tumors, including the possibility that the targeting moiety could be matched to individual patient genetic profiles (patient-specific therapeutics).
© (2009) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
C. W. Spangler, A. Rebane, J. Starkey, and M. Drobizhev "Targeted two-photon PDT photo-sensitizers for the treatment of subcutaneous tumors", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803Z (13 July 2009);

Back to Top